研究性重组肉毒疫苗rBV A/B在已有肉毒类毒素免疫志愿者中的安全性和免疫原性
这是一项开放标签、非对照研究,纳入45名曾接种研究性五价肉毒类毒素的健康志愿者,单次肌内注射0.5 mL、40微克rBV A/B。接种后4周,抗BoNT/A与抗BoNT/B中和抗体浓度≥4倍升高的参与者分别为37/45(82.2%)和39/45(86.7%),达到主要免疫原性终点;未发生严重或非预期不良事件。
要点
- 45名参与者全部完成研究,42/45(93.3%)出现至少1项治疗中出现的不良事件(TEAE)。
- 218例次报告TEAE中138例次(63.3%)与治疗相关,多为轻度注射部位反应。
- 接种后4周抗BoNT/A、抗BoNT/B中和抗体≥4倍升高者分别为37/45(82.2%)、39/45(86.7%)。
核心结论
- 单次0.5 mL剂量rBV A/B在既往接种五价肉毒类毒素的参与者中安全、耐受良好且具有免疫原性。
- 作者认为,对已具备BoNT免疫者接种rBV A/B的耐受性和免疫原性特征,支持其未来可能用于为肉毒中毒实验室工作人员提供职业防护。
- 几乎所有研究参与者均捐献了超免疫血浆用于生产BIG-IV(BabyBIG®)。
研究设计与样本
- 开放标签、非对照研究,研究对象为既往接种过研究性五价肉毒类毒素的健康志愿者。
- 单次肌内注射0.5 mL(40微克)rBV A/B。
- 接种后约每2周采集血清,检测抗BoNT/A和抗BoNT/B中和抗体浓度(NAC)。
- 接种后12周内通过临床和实验室监测识别局部及全身治疗中出现的不良事件(TEAE),6个月时电话随访进行额外安全性评估。
- 主要免疫原性终点为接种后第4周≥50%的参与者NAC升高≥4倍;共45名参与者入组并全部完成研究。
主要发现
- 45名参与者全部完成研究。
- 42/45(93.3%)参与者经历至少1项TEAE。
- 218例次报告TEAE中138例次(63.3%)与治疗相关,其中大多数为轻度注射部位反应。
- 未发生严重或非预期不良事件。
- 接种后第4周,抗BoNT/A NAC升高≥4倍者为37/45(82.2%),抗BoNT/B NAC升高≥4倍者为39/45(86.7%),达到主要免疫原性终点。
关键数值与推荐
- 主要免疫原性终点:接种后第4周≥50%的参与者NAC升高≥4倍。
- 实际达到该终点:抗BoNT/A为37/45(82.2%),抗BoNT/B为39/45(86.7%)。
- 干预剂量与途径:单次0.5 mL(40微克)肌内注射。
- 安全性监测:接种后12周临床和实验室监测,6个月时电话随访。
- 临床试验注册号:NCT01701999。
临床怎么用
- 作者认为,rBV A/B对已具备BoNT免疫者的耐受性和免疫原性特征,支持其未来可能用于为肉毒中毒实验室工作人员提供职业防护。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We undertook an open-label, uncontrolled study of investigational recombinant botulinum vaccine for botulinum neurotoxin (BoNT) serotypes A and B (rBV A/B) to assess its safety and immunogenicity in healthy volunteers who had been previously immunized with investigational pentavalent botulinum toxoid. Study participants who wished to do so could donate their hyperimmune plasma for production of Human Botulism Immune Globulin Intravenous (BIG-IV, BabyBIG®). STUDY DESIGN: A single 0.5 ml (mL), 40-microgram intramuscular injection of rBV A/B was administered to study participants. Post-vaccination sera collected at approximately 2-week intervals were evaluated for anti-BoNT/A and anti-BoNT/B neutralizing antibody concentrations (NAC). Local and systemic treatment-emergent adverse events (TEAEs) were identified by clinical and laboratory monitoring for 12 weeks post-vaccination with a final telephone follow-up for additional safety assessment at 6 months. The primary endpoint for immunogenicity was a ≥4-fold rise in NAC in ≥50% of participants by Week 4 post-vaccination. RESULTS: All 45 enrolled participants completed the study. Forty-two of 45 participants (93.3%) experienced at least one TEAE. Overall, 138 of 218 (63.3%) reported TEAEs were treatment-related, the majority of which were mild injection-site reactions. No serious or unexpected adverse events occurred. The study achieved its primary immunogenicity endpoint with 37/45 (82.2%) participants and 39/45 (86.7%) participants having a ≥4-fold rise in NAC to anti-BoNT/A and to anti-BoNT/B, respectively, by Week 4 post-vaccination. CONCLUSION: A single 0.5 mL dose of rBV A/B was safe, well-tolerated and immunogenic in participants previously immunized with pentavalent botulinum toxoid. The tolerability and immunogenicity characteristics of rBV A/B vaccination of individuals with existing BoNT immunity support its potential future use to provide occupational protection to botulism laboratory workers. Almost all study participants donated hyperimmune plasma for production of BIG-IV. ClinicalTrials.gov registration number: NCT01701999.
引用
- Khouri JM, Motter RN, Arnon SS, et al. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Vaccine. 2018. PMID: 29475762. doi:10.1016/j.vaccine.2018.02.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。